A multicentre trial with topotecan, mitoxantrone and cytarabine in patients with relapsed or refractory AML or CML in blast crisis - Interim results.

被引：0
|
作者：
Hoechsmann, B
Doehner, H
Ganser, A
Heil, G
Denzlinger, C
Einsele, H
Duerk, H
Raghavachar, A
Hoelzer, D
Bergmann, L
机构：
[1] Univ Ulm, Ulm, Germany
[2] MHH, Hannover, Germany
[3] Univ Tubingen, Tubingen, Germany
[4] Sankt Marien Hosp, Hamm, Germany
[5] Klinikum Wuppertal, Wuppertal, Germany
[6] Univ Frankfurt, D-6000 Frankfurt, Germany
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4564
引用
收藏
页码：213B / 213B
页数：1
相关论文
共 50 条
  • [21] CHARACTERIZATION OF PATIENTS WITH RELAPSED OR REFRACTORY AML IN CONTINUED FOLLOW-UP AFTER TREATMENT WITH VOSAROXIN/CYTARABINE VS PLACEBO/CYTARABINE IN THE VALOR TRIAL
    Pigneux, A.
    Ravandi, F.
    Ritchie, E. K.
    Lancet, J. E.
    Craig, M. D.
    Horst, H. A.
    Maertens, J.
    Derigs, H. G.
    Heuser, M.
    Wei, A.
    Hogge, D.
    Clark, R.
    Ward, R.
    Smith, J. A.
    Craig, A. R.
    Stuart, R. K.
    HAEMATOLOGICA, 2016, 101 : 381 - 381
  • [22] Asciminib as a Bridge to Allogenic Transplant in 3 Patients With Relapsed/Refractory Philadelphia Chromosomepositive ALL or CML Lymphoid Blast Crisis Refractory/Intolerant to Ponatinib
    Kumar, Nikhil M.
    Bhargava, Rahul
    Rastogi, Neha
    Yadav, Chitresh
    Swaminathan, Anusha
    Garg, Paritosh
    Kothari, Akriti
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S283 - S284
  • [23] Clofarabine plus cytarabine compared to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): Results from the phase III CLASSIC 1 trial
    Faderl, S.
    Wetzler, M.
    Rizzieri, D.
    Schiller, G. J.
    Jagasia, M. H.
    Stuart, R. K.
    Ganguly, S.
    Avigan, D.
    Craig, M.
    Collins, R.
    Maris, M. B.
    Kovacsovics, T.
    Goldberg, S.
    Seiter, K.
    Hari, P.
    Ravandi, F.
    Wang, E. S.
    Eckert, S.
    Huebner, D.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results
    Klisovic, Rebecca B.
    Wang, Hongyan
    Walker, Alison
    Walsh, Katherine
    Vasu, Sumithira
    Garzon, Ramiro
    Devine, Steven M.
    Wang, Jiang
    Garr, Celia
    Norris, Adam
    Byrd, John C.
    Grever, Michael R.
    Blum, William
    Chan, Kenneth K.
    Marcucci, Guido
    BLOOD, 2012, 120 (21)
  • [25] Venetoclax Plus High-Dose Cytarabine and Mitoxantrone (HAM-Ven) As Salvage Treatment for Relapsed/Refractory AML: Updated Results of the Phase-I/II SAL Relax Trial
    Ruhnke, Leo
    Schliemann, Christoph
    Mikesch, Jan-Henrik
    Stelljes, Matthias
    Fransecky, Lars
    Steffen, Bjoern
    Kaufmann, Martin
    Burchert, Andreas
    Rank, Andreas
    Hanoun, Maher
    Hoellein, Alexander
    Kraus, Sabrina
    Haenel, Mathias
    Schaefer-Eckart, Kerstin
    Haake, Annett
    Fiebig, Frank
    Zukunft, Sven
    Middeke, Jan Moritz
    Kunadt, Desiree
    Schetelig, Johannes
    von Bonin, Malte
    Roehnert, Maximilian Alexander
    Oelschlaegel, Uta
    Stoelzel, Friedrich
    Baldus, Claudia D.
    Serve, Hubert
    Wermke, Martin
    Bornhaeuser, Martin
    Roellig, Christoph
    BLOOD, 2023, 142
  • [26] Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study.
    Vey, N
    Kantarjian, H
    Beran, M
    O'Brien, S
    Cortes, J
    Giles, FJ
    Koller, C
    Estey, E
    BLOOD, 1998, 92 (10) : 235A - 235A
  • [27] A PHASE I TRIAL OF LENALIDOMIDE IN COMBINATION WITH INTERMEDIATE DOSE CYTARABINE (IDC) IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) PATIENTS
    Vigil, E.
    Griffiths, A.
    Thompson, E.
    Brady, E.
    Dickey, M.
    Ford, A.
    Wang, S.
    Wetzler, M.
    HAEMATOLOGICA, 2012, 97 : 33 - 33
  • [28] Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial
    Roellig, Christoph
    Fransecky, Lars
    Hanoun, Maher
    Steffen, Bjorn
    Kraus, Sabrina
    Schliemann, Christoph
    Haake, Annett
    Fiebig, Frank
    Zukunft, Sven
    Alakel, Nael
    Middeke, Jan Moritz
    Bornhaeuser, Martin
    Stoelzel, Friedrich
    Schetelig, Johannes
    Ruhnke, Leo
    Kramer, Michael
    Von Bonin, Malte
    Roehnert, Maximilian Alexander
    Oelschlaegel, Uta
    Baldus, Claudia D.
    Serve, Hubert
    Wermke, Martin
    BLOOD, 2022, 140 : 3327 - 3328
  • [29] Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial
    Faderl, Stefan
    Wetzler, Meir
    Rizzieri, David
    Schiller, Gary
    Jagasia, Madan
    Stuart, Robert
    Ganguly, Siddhartha
    Avigan, David
    Craig, Michael
    Collins, Robert
    Maris, Michael
    Kovacsovics, Tibor
    Goldberg, Stuart
    Seiter, Karen
    Hari, Parameswaran
    Greiner, Jochen
    Vey, Norbert
    Recher, Christian
    Ravandi, Farhad
    Wang, Eunice S.
    Vasconcelles, Michael
    Huebner, Dirk
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (20) : 2492 - 2499
  • [30] MITOXANTRONE, ETOPOSIDE AND CYTARABINE (MEC) CAN INDUCE DEEP COMPLETE REMISSION AND IS AN EFFECTIVE BRIDGE THERAPY TO ALLOTRANSPLANTATION (SCT) IN REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA (AML) PATIENTS
    Marconi, G.
    Talami, A.
    Abbenante, M. C.
    Paolini, S.
    Sartor, C.
    Parisi, S.
    De Polo, S.
    Nanni, J.
    Bertamini, L.
    Ragaini, S.
    Olivi, M.
    Fontana, M. C.
    Bochicchio, M. T.
    Ottaviani, E.
    Baldazzi, C.
    Testoni, N.
    Martinelli, G.
    Cavo, M.
    Papayannidisdegrees, C.
    Curti, A.
    HAEMATOLOGICA, 2019, 104 : 134 - 134
12345